CADTH Canadian Drug Expert Committee recommendation : indication : vision loss, inherited retinal dystrophy. Voretigene neparvovec (Luxturna -- Novartis Pharmaceuticals Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Vision disorders.

Vision, Ocular.

Physical Description:

1 online resource (10 pages) : illustrations

Edition:

First edition.

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2020.

Summary:

Voretigene neparvovec has a Health Canada indication for the treatment of adult and pediatric patients with vision loss due to IRD caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells. Voretigene neparvovec is a vector-based gene therapy designed to deliver a normal copy of the gene encoding the human RPE65 to cells of the retina in persons with reduced or absent levels of biologically active RPE65. It is available as vector genomes/mL concentrate for solution for subretinal injection and the Health Canada-approved dose is 1.5 x 1011 vector genomes (vg) for each eye.

Notes:

Description based on publisher supplied metadata and other sources.